Research over the past quarter century has identified cyclin D-dependent kinases, CDK4 and CDK6, as the major oncogenic drivers among members of the CDK superfamily. CDK4/6 are rendered hyperactive in the majority of human cancers through a multitude of genomic alterations. Sustained activation of these protein kinases provides cancer cells with the power to enter the cell cycle continuously by triggering G1-S-phase transitions and dramatically shortening the duration of the G1 phase. It has also become clear, however, that CDK4/6 effectively counter cancer cell-intrinsic tumor suppression mechanisms, senescence and apoptosis, which must be overcome during cell transformation and kept at bay throughout all stages of tumorigenesis. As a central 'node' in cellular signaling networks, cyclin D-dependent kinases sense a plethora of mitogenic signals to orchestrate specific transcriptional programs. As the complexity of the cellular signaling network regulated by these oncogenic kinases unfolds, much remains to be learned about its architecture, its dynamics and the consequences of its perturbation.
INTRODUCTION
Cyclin-dependent kinases (CDKs) govern cell cycle phase transitions in mammals and boost global gene transcription. It has been appreciated that cancer cells often rely on augmented CDK signaling, which manifests in an increased rate of cell cycling, cellular hyperproliferation as well as acquired genomic and chromosomal instability. 1 Over the past 2 decades, cyclin D-dependent kinases (CDK4 and CDK6) have been identified as the major oncogenic drivers among cell cycle CDKs. Both kinases are rendered hyperactive through a broad variety of mechanisms in human cancer, including frequent amplification or mutation of their genes. [2] [3] [4] [5] [6] Moreover, the CCND1 and CDKN2 loci-encoding specialized CDK4/6 regulatory subunits, cyclin D1 and INK4 proteins (inhibitors of CDK4), respectively-show some of the highest frequencies of amplification and deletion among cancer genes across a broad spectrum of human tumors. 5, [7] [8] [9] [10] On top of this, it has become clear that several tumor types, including leukemias, breast and lung cancers, are addicted to cyclin D-dependent kinase activity. [11] [12] [13] [14] At the mechanistic level, recent studies have revealed pro-tumorigenic functions of CDK4/ 6 beyond cell cycle progression; these findings provide further weighty incentives for the development and application of specific CDK4/6 inhibitors in cancer therapy. [13] [14] [15] [16] [17] [18] [19] We begin this review with an up-to-date summary of the basic signaling mechanisms employed by cells to activate and restrain CDK4 and CDK6 function (upstream signaling). Part two covers, in broad strokes, phosphorylation-dependent signaling themes by which the kinases, once active, exert their oncogenic functions (downstream signaling). The third chapter places cyclin D-dependent kinases at the center of cellular signaling networks and considers the complexity of cross-talk between pathways within the network. Building on this, the fourth part highlights the recent progress made in our understanding of the biological consequences of aberrant cyclin D-dependent kinase signaling in cancer cells. Finally, we discuss how these novel insights impact on the application of drug development efforts and summarize the current progress made with small-molecule inhibitors of CDK4/6.
DETERMINANTS OF CYCLIN D-DEPENDENT KINASE ACTIVITY
This review starts with a discovery made by Croce and colleagues more than a quarter century ago: the investigators found that several B-cell neoplasms, including multiple myeloma and mantle cell lymphoma (MCL), harbor a characteristic chromosomal translocation, which juxtaposes segment q13 of chromosome 11 (11q13) adjacent to the enhancer region of the human antibody heavy chain locus positioned on chromosome 14 (14q32). [20] [21] [22] [23] The transcriptionally activated oncogene located at the 11q13 breakpoint, originally termed bcl-1 (B-cell lymphoma/leukemia 1) or PRAD1-due to a similar chromosomal rearrangement observed in parathyroid adenomas 24, 25 -was subsequently identified as a novel member of the cyclin gene family and renamed cyclin D1. 26, 27 The molecular functions of cyclin D1 as well as its two relatives, cyclins D2 and D3, came to light in quick succession: the three distinguishable D-type cyclins serve as regulatory subunits to specifically activate the cyclin-dependent kinase type 4, CDK4 28 ( Figure 1a ), giving rise to three distinct binary cyclin D-CDK4 complexes. 29, 30 A protein kinase closely related to CDK4, termed CDK6, was subsequently characterized as an alternative catalytic subunit that is selectively activated by D-cyclins in a similar fashion (Figure 1a) . 31, 32 D-type cyclins When not bound to their catalytic partner, D-cyclin subunits are relatively unstable proteins, frequently labeled with the sobriquet 'sensors of mitogenic signals'. This notion seems a better reflection of their characteristics than their official name: unlike most other cyclins that are strictly periodically expressed (that is, 'cycling') when cells pass through the different phases of the cell cycle, the protein levels of cyclin D1, D2 and D3 adjust with some precision to the presence of mitogens in the cellular environment. 33 There are at least three principal mechanisms that augment cyclin D abundance and thus activation of CDK4/6: (1) increased transcription of the cyclin D genes driven by a variety of transcription factors, primarily those that convey mitogenic signaling cues (c-Jun, c-Fos, ATF2, Ets-2, SP1, TCFs (T-cell factor/lymphoid enhancer factor), MYC), are activated by cytokines (Signal transducers and activators of transcription (STATs), nuclear factor-kB) and others (Notch, Krueppel-like factors (KLFs), cAMP response element-binding protein (CREB)), [34] [35] [36] [37] [38] (2) elevated cyclin D protein translation, mediated through PI3K-Akt-mTOR (mammalian target of rapamycin)-S6K1 (S6 kinase 1) signaling 39, 40 and (3) stabilization and nuclear localization of the cyclin D protein, regulated by C-terminal phosphorylation of cyclin D itself (at T286 in cyclin D1).
That is, the cellular signaling apparatus effectuates increases in nuclear cyclin D protein levels through inhibition of GSK3b and likely related T286 kinases, which otherwise phosphorylate D-cyclin, thereby promoting its nuclear export, ubiquitylation and proteasomal degradation. [41] [42] [43] [44] This phosphorylation-dependent proteolysis of D-cyclins is mediated through at least three distinct F-box proteins (FBXO5, FBXW8 or DNA-damage inducible FBXO31), all of which recruit phosphorylated D-cyclin to the Skp, Cullin and F-box (SCF) ubiquitin ligase complex. [45] [46] [47] The determination of the X-ray crystallographic structures of cyclin D-CDK4 complexes has provided unprecedented insights into the mechanism of kinase activation by the D-cyclin subunits. 48, 49 The mode of cyclin D binding to CDK4 seems unique among CDK-cyclin interactions: the cyclin D-CDK4-binding surface is surprisingly small, involving only the CDK4 N-terminal fold of the kinase subunit. It follows that-in marked contrast to the activation mechanism of all other binary CDK-cyclin complexes structurally solved to date-cyclin D binding to CDK4 does not cause spontaneous remodeling of the catalytic subunit into an active conformation, suggesting that other cofactors are required for kinase activation (Figure 1b) . 48, 49 Cip/Kip proteins Cip/Kip proteins constitute a second, entirely distinct class of regulatory subunits, comprising p21, p27 and p57 ( Figure 1a ). The mode of action of these double-faced regulators is complex as they can act as both positive and negative regulatory subunits of CDK4/6, depending on their phosphorylation status 33, 50 ( Figures  1a and b) . The evidence for their role as activating subunits stems from three key observations: first, catalytically active cyclin D-CDK4/6 complexes are bound to Cip/Kip proteins ( Figure 1b) . Secondly, cyclin D-CDK4/6 assembly-and consequently activation of the kinase subunit-requires the presence of Cips/Kips. [51] [52] [53] [54] Thirdly, p21, p27 and p57 harbor bipartite nuclear localization sequences, whereas CDK4, CDK6 and D-cyclins do not. Thus, binding to Cips/Kips is thought to mediate (a) CDK4 and CDK6 with their regulatory subunits. Cells possess three distinct families of regulatory subunits: activating D-type cyclins (top), negative regulatory INK4 proteins (bottom) and Cips/ Kips, which can act as both inhibitors and activators, depending on their phosphorylation status (see below). The activation loop (or T-loop), an important regulatory sequence of the catalytic subunit itself, is also highlighted. Gene names are set in upper-case italic if they differ from the protein description. (b) The CDK4/6 signaling cycle. Depending on the abundance and stoichiometry of the three regulatory subunits (D-cyclins, Cips/Kips, INK4s) in the cell, each of the catalytic subunits (CDK4 or CDK6) can either bind to a D-type cyclin and a Cip/Kip protein, thus forming a trimeric holoenzyme (1), or can associate with an INK4 inhibitor, which prevents further activation of CDK4/6 by trapping it in a dimeric, catalytically inactive state (5) . Once a trimeric holoenzyme has formed, phosphorylation of the Cip/Kip subunit by non-receptor tyrosine kinases (NRTKs) is thought to convert the latter from a bound inhibitor to a bound non-inhibitor (2) . This allows subsequent T-loop phosphorylation of the catalytic subunit, a required event in the activation sequence, by the CDK-activating kinase, CAK (3). The derived, active holoenzyme now initiates substrate phosphorylation, but this process can be specifically inhibited by INK4 proteins, which-when present in the cell-effectively bind to and inhibit the catalytic subunit and disassemble the holoenzyme (4). Alternatively, phosphatases (Pase) may counter the kinase activation process by reversing Cip/Kip and T-loop phosphorylation (6) . (c) Conceptual summary of the six direct signaling cues-three activating (red), three inhibitory (green)-that determine the activity of cyclin D-dependent kinases in the cell. In aggregate, and in terms of cell signaling, we refer to these regulating cues as the direct input layer of the CDK4/6 signaling landscape. Cip/Kip-P, Cip/Kip phosphorylated in its 3 10 helix (see text for details).
nuclear import of cyclin D-dependent kinases, thereby providing access to critical substrates. 53, 55, 56 On the other hand, unphosphorylated p21 and p27 proteins-often present in cells undergoing contact inhibition of cell growth or serum starvation-can directly inhibit CDK4/6 enzymatic activity in in vitro assays and upon ectopic expression in cells by directly blocking the kinase's active site. 52, [57] [58] [59] [60] As mentioned above, Cip/Kip proteins interconvert from an inhibitory into an activation mode through phosphorylation on tyrosine residues located in the 3 10 helix of p21 (Y76) or p27 (Y88, Y89), a modification catalyzed by non-receptor tyrosine kinases, such as Abl, Src and Lyn (Figure 1b) . [61] [62] [63] [64] Phosphorylation of the 3 10 helix relieves its occlusion from the kinase's active site and allows CDK4/6 T-loop phosphorylation by the CDK-activating kinase-hence both events are necessary to confer CDK4/6 activation ( Figure 1b) . 64, 65 Activation loop (T-loop) phosphorylation CDK catalytic subunits possess a bilobal structure where the adenosine triphosphate (ATP)-binding site is positioned within the central mouth with the T-loop forming a 'tongue' at its base. 66 Phosphorylation of the T-loop by the CDK-activating kinase-at T172 in CDK4 and T177 in CDK6-is thought to take place after the cyclin D-CDK4/6-Cip/Kip ternary complex has formed (Figure 1b) . [67] [68] [69] This sequence of events renders the kinases fully active by flattening the T-loop and causing it to move out of the catalytic cleft to assume a 'loop out' conformation, in which the loop aids in cyclin and substrate binding. 48 The prevailing view is that CDK7, in association with cyclin H and Mat1, acts as a CDK4/6 activating kinase, but other kinases may be involved in T-loop phosphorylation. 70 It is clear that phosphorylation of the T-loop-as well as the priming phosphorylation of Cips/Kips-are countered by phosphatases in vivo, but the identity of these enzymes remains to be determined (Figure 1b ).
INK4
proteins INK4 proteins (p15, p16, p18 and p19) constitute the third category of regulatory subunits (Figure 1a) , evolved specifically to inhibit cellular CDK4/6 catalytic activity without directly affecting the function of other cyclin-CDK complexes. 33, [71] [72] [73] [74] [75] Not only does INK4 protein binding to the ternary cyclin D-CDK4/6-Cip/Kip holoenzyme directly distort the kinase's ATP-binding site and misalign critical catalytic residues, it also propagates conformational changes throughout the catalytic subunit, thereby substantially reducing the cyclin D-binding interface and preventing the interaction with Cips/Kips. [76] [77] [78] Consequently, if cellular INK4 protein levels rise high-as is often the case when cancer cells experience loss-of-function of the retinoblastoma tumor suppressor protein, a known repressor of INK4 expression-INK4 and CDK4/6 subunits assemble into binary complexes, which are devoid of any kinase activity (Figure 1b) . 73, 79, 80 More importantly, when cells encounter potent physiological triggers of INK4 expression, such as transforming growth factor (TGF)b, DNA-damage and senescence, oncogenic stress or cellular aging, a similar subunit rearrangement is likely to take place. [81] [82] [83] [84] [85] [86] The result is the dissociation of Cips/Kips and D-cyclins from the holoenzyme, the rapid degradation of the freed and unstable D-cyclin proteins 31 and the effective cessation of CDK4/6 enzymatic activity (Figure 1b) . Before discussing this major route of signaling, it is important to note that a second, 'kinase-independent' function is also at play once cyclin D-CDK4/6-Cip/Kip holoenzymes have formed. Although Cip/Kip proteins inhibit CDK2, most of these proteins are found in complex with cyclin D-dependent kinases in proliferating cells. As the unbound cellular pool of Cips/Kips is limited, these regulators are thus effectively titrated away from CDK2 into the CDK4/6-containing complex, resulting in the activation of CDK2 along with cyclin D-dependent kinases. 33, 87 It follows that CDK2 often functions in a redundant fashion in cells to engage downstream signaling pathways, but catalytically inactive CDK4/6 holoenzymes, as well as specific ATPcompetitive small-molecule inhibitors have provided valuable means to experimentally distinguish between the two signaling modalities; these tools have unveiled the critical functional importance of cyclin D-dependent kinase activity, especially in cancer cells. For example, the ability to drive tumorigenesis and cancer cell-cycle progression, to suppress senescence and P P P P P P P P P P P P P P P
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CDKN1A CDKN2B P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P The octameric MEP50/PRMT5 complex then catalyzes the symmetric dimethylation of arginine residues in histone H3 and H4 (H3R8, H4R3) at gene promoters, which is associated with compaction of the chromatin structure and transcriptional silencing of target genes, such as CUL4A and CUL4B. The identity of the transcription factors that drive expression of these two genes in the absence of PRMT5 activity remains to be determined.. apoptosis, as well as to regulate metabolism and cancer cell drug resistance is largely kinase-dependent and requires the phosphorylation of critical substrates. [11] [12] [13] [14] [15] [88] [89] [90] [91] [92] [93] Direct phosphorylation targets In the large majority of documented cases, CDK4, CDK6 and other members of the CDK superfamily phosphorylate their substrates on serine/threonine residues preceding a proline (the 'S/T-P motif'). Phosphorylation events of this kind are referred to as proline-directed, and CDKs as proline-directed protein kinases. 94 Substrate phosphorylation is further aided by the proximal presence of basic amino acids (K or R), located anywhere between the þ 2 (S/T-P-K/R) and the þ 5 position (S/T-P-X-X-X-K/R) relative to the phosphorylated residue, although exceptions from this rule do exist (in some cases basic residues are absent, or may be localized further downstream in the sequence). 15, 95 Furthermore, phosphorylation-if it occurs-frequently involves multiple of the above-described sites for a given substrate ('multisite phosphorylation'). Although, as mentioned above, these principles of phosphorylation-site recognition typically apply to all members of the CDK superfamily, their protein targets vary widely in identity and number, with cyclin D-dependent kinases clearly standing out due to their fastidious substrate selectivity. No other CDK substrates exemplify this attribute better than histones, which are readily phosphorylated by all cell cycle CDKs, except CDK4 and CDK6. 15, 33 The best characterized substrates of cyclin D-dependent kinases-defined by means of in vivo and in vitro phosphorylation data, as well as the functional requirement to effectuate, at least in part, kinase-mediated cell responses-are the retinoblastoma protein, RB1, and its relatives, RBL1 and RBL2 28, [95] [96] [97] [98] [99] [100] [101] (Table 1 , Figure 2a ). Other substrates meeting these three criteria include the SMAD2, SMAD3 and FOXM1 transcription factors, as well as the transcriptional corepressor MEP50. 15, 102, 103 Consistent with this, the CDK4/6-activating subunit, cyclin D1, was found to occupy gene promoters across the genome, indicating that the kinase holoenzyme has a role in the regulation of the transcriptional machinery, including transcription factors and cofactors. 104 A recent proteome-wide in vitro kinase substrate screen, based on combined computational and experimental approaches, has considerably expanded the number of previously described phosphorylation targets; several of these novel substrates were also shown to be phosphorylated by the kinases in cells. 15 Intriguingly, this study also revealed that the substrate selectivity of the CDK4-and CDK6-containing complexes differs, with CDK4 being more fastidious and phosphorylating fewer substrates.
Signaling through the RB/E2F pathway RB or 'pocket' proteins possess a variety of docking sites, most of which are localized within the central pocket, which is flanked by N-and C-terminal regions. These docking sites allow RB1 and its relatives to nucleate the assembly of multi-protein complexes by binding to an array of signaling proteins simultaneously, including E2F-DP1 transcription factor heterodimers-which primarily occupy gene promoters-and chromatin-modifying enzymes. 105, 106 Recruitment of RB proteins to gene promoters is principally mediated through E2F1 to 5, but the RB-E2F interactions are regulated in a highly coordinated fashion: while E2F1, E2F2 and E2F3 primarily recruit RB1, E2F4 is typically found in complex with either of the three RB family members (RB1, RBL1 or RBL2). By contrast, E2F5 shows the highest affinity for RBL2 (Figure 2b , top panel). RB1 and its relatives then tether DNA methylases, histone deacetylases, specific histone methylases and demethylases to RB-E2F occupied gene promoters, leading to chromatin compaction and transcriptional silencing (Figure 2b , top panel). [107] [108] [109] [110] Activation of cyclin D-dependent kinases reverses this process: phosphorylation of RB1, RBL1 or RBL2 at their N-and C-terminal regions is thought to destabilize their interaction with E2F and DP1 proteins and to diminish the binding between RB proteins and histone deacetylase 1. [111] [112] [113] [114] [115] [116] The result is the disassembly of RB-containing transcriptional repressor complexes and the derepression of all genes occupied by E2Fs 1-5, but only the 'activating' E2Fs (E2F 1-3) switch from a repressive to an active mode to drive transcription of their target genes, whereas the 'repressive' E2Fs (E2F4 and 5) do not positively regulate transcription and are thought to be exported from the cell nucleus 117, 118 ( Figure 2b, lower panel) . Conversely, when CDK4/6 activity fades, transcriptional repression is reestablished.
Genes transcribed by E2Fs 1-3 encode proteins that make up the DNA replication apparatus, the DNA repair machinery and DNA-damage checkpoints, chromatin and its regulators, as well as signaling proteins that mediate feedforward and feedback signaling. [119] [120] [121] Thus, CDK4/6-RB-E2F signaling triggers expression of a defined cadre of proliferation-associated genes that mediate the transition across the G1-S border of the cell cycle. This gene expression program is henceforth referred to as the 'G1-S transcriptional program', comprising 'G1-S signature genes'.
Activation of FOXM1 signaling FOXM1 possesses both DNA binding and transactivation domains and functions as a potent activator of gene expression, although cases of FOXM1-mediated transcriptional repression have been described. 122, 123 As is the case with RB proteins, CDK4/6 phosphorylates FOXM1 primarily at its N-and C-terminal sequences, but the functional consequences are different: first, phosphorylation of FOXM1 curbs its proteasomal turnover, thus causing stabilization of the FOXM1 protein (Figure 2c) . Second, C-terminal phosphorylation on multiple sites directly induces transactivation, with the number of phosphorylated residues being directly proportional to the amplitude of FOXM1 transcriptional activity. 15 This indicates that spatial and temporal gradients of CDK4/6 activity are converted into a 'graded' transcriptional response. Intriguingly, the transcriptional signature of this response is reminiscent of the E2F transcriptional program, comprising primarily cell cycle genes required for checkpoint integrity, S-phase entry and mitotic regulation. 15, 124, 125 FOXM1 binds to the DNA through forkhead-responsive elements, which can also recruit FOXOs, suggesting that both factors compete for binding to the same forkhead-responsive element, even though their functions are often opposed. For example, while FOXOs repress expression of cell cycle genes, FOXM1 drives their transcription to promote G1-S and G2-M-phase transitions. [125] [126] [127] In an intriguing model, cyclin D-dependent kinases-by augmenting FOXM1 protein levels-switch transcriptional programs from cell cycle inhibitory to activating by changing the balance of the two factors in favor of FOXM1 (Figure 2c ).
Twisting TGFb signaling TGFb signaling elicits transcriptional responses that are highly cell context-dependent, but frequently involve anti-proliferative and mesenchymal gene signatures. 128 Signaling is initiated by the presence of growth-inhibitory TGFb in the extracellular environment, which triggers phosphorylation of receptorregulated SMADs, SMAD2 and SMAD3, by TGFb type I (TGFbRI) receptors. This causes nuclear translocation of the SMAD2 and SMAD3 transcription factors and creates docking sites for SMAD4, which functions as a shared partner (Figure 2d, upper panel) . As a result, SMAD2, 3 and 4 assemble into heterotrimers, the principal functional units that can both inhibit or activate transcription of target genes through SMAD-binding elements. For example, SMAD signaling suppresses the transcription of MYC, while driving expression of the CDK inhibitors p15 (CDKN2B) and p21 (CDKN1A). 128 Cyclin D-dependent kinases counter cytostatic TGFb signaling and negate its anti-proliferative transcriptional responseincluding the induction of p15-by phosphorylating SMAD2 and SMAD3 at multiple sites, positioned primarily in the SMAD linker region 102, 129 ( Figure 2d, lower panel) . Moreover, linker phosphorylation by CDK4/6 may switch or skew SMAD signaling from a cytostatic to a pro-mesenchymal mode, thus promoting cancer cell invasion in addition to proliferation. 129 Signaling through histone methylation Besides controlling the transactivation potential and the 'free pool' of transcription factors, methylation of histone proteins provides a conceptually distinct mechanism utilized by cyclin D-dependent kinases to regulate transcription. We mentioned above that CDK4/6 counter RB-mediated recruitment of histone methylases and specific demethylases to gene promoters (Figure 2b ). In addition, aberrant activation of CDK4/6 in tumors has been linked to increased dimethyl arginine modifications of histones H3 and H4 (H3R8 and H4R3), 103 repressive histone marks deposited by the methyltransferase PRMT5 in association with its positive regulatory subunit, MEP50 [130] [131] [132] (Figure 2e , upper panel). CDK4/6 phosphorylates MEP50 to activate PRMT5, resulting in transcriptional repression of target genes, including CUL4A and CUL4B
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( Figure 2e, lower panel) . The prevailing view is that both genes, encoding core components of the CUL4-RING-based E3 ubiquitin ligases, mediate the degradation of CDT1; hence the latter must be inactivated during S-phase to prevent DNA rereplication and genomic instability. Thus, prolonged activation of CDK4/6 promotes genomic instability through transcriptional repression of target genes required for S-phase checkpoint fidelity.
CDK4/6 AS CENTRAL NODE IN COMPLEX SIGNALING NETWORKS Although signaling through cyclin D-dependent kinases has often been represented by a linear p16-CDK4/6-RB-E2F pathway-in which p16 inhibits the kinase, thereby abrogating RB phosphorylation and keeping E2F transcription factors at bay-it is now appreciated that cyclin D-dependent kinases phosphorylate a variety of substrates, thus leading to pathway branching (Figure 2a) . Conversely, a multitude of signaling cues converges on the CDK4/6 'node' to control kinase activation (Figure 1c ). In addition, the 'effector' pathways engaged by substrate phosphorylation (Figures 2b-e) are often intertwined, with considerable cross-talk between them. Other key features of cyclin D-dependent signaling are positive and negative regulatory feedback loops-which allow the system to balance itself-as well as feedforward signaling mechanisms. Thus, cyclin D-dependent kinases form a central 'node' in a complex signaling network that shapes the overall transcriptional and biological response of cells to activation or inhibition of the kinases (Figure 3 ).
Effector pathway cross-talk Several lines of evidence suggest that the signaling pathways regulated by CDK4/6 are highly intertwined. For example, SMAD3 can directly bind to E2F4/5 and RBL1, forming a transcriptional repressor complex that targets atypical SMAD-binding sites on Figure 3 . Intracellular signaling network centered on CDK4/6. Simplified model integrating upstream regulatory pathways and signaling proteins, the direct input layer (1), the central CDK4/6 'node' (2), the direct output layer (3), downstream signaling entities and the G1-S transcriptional program (4) that ultimately drives cell cycle entry. Protein components communicate through stimulatory (green arrows) and inhibitory signals (red arrows) transmitted either through transcriptional or other mechanisms, including phosphorylation. Individual pathways are often branched and intertwined-for example, E2F, RBL1 and SMADs jointly repress the MYC gene-to form a complex circuitry. Note the presence of negative and positive feedback signaling loops (NFS and PFS, respectively) in the system. For example, by relieving RB1's repressive function, cyclin D-dependent kinases increase the levels of p16, which in turn counters the activity of the kinases. This negative feedback signaling loop is often disabled in cancer cells. PFS loops are provided by E2Fs, which induce transcription of their own genes, while E-cyclins and SKP2-via degradation of p27-activate CDK2; this leads to further substrate phosphorylation and transcription of G1-S genes. The latter also encode feedforward signaling (FFS) proteins, such as MYB, likely mediating subsequent transcriptional waves during cell cycle progression. pre-RC, pre-replication complex.
DNA, positioned adjacent to an E2F site. Occupation of this composite-binding site, coined TGFb-inhibitory element, by the SMAD3-E2F4/5-RBL1 complex not only results in repression of MYC transcription 133 ( Figure 3 ), but to co-occupation of target genes by SMAD3 and E2F4/5 genome-wide. 134 A second example along this line is provided by the observation of FOXM1 and the three activating E2Fs (E2F1, 2, 3) regulating expression of an overlapping set of target genes, including genes expressed at the G1-S border and S-phase entry, such as DNA repair genes, cyclin E and MYB 15 ( Figure 3 ). In addition, FOXM1 can be repressed by RB1 through direct binding. 135 Yet another example of cross-talk between two effector (downstream) pathways is exemplified by PRMT5-mediated methylation of E2F1 (Figure 3 )-in addition to histones (Figure 2e )-which augments E2F1-mediated transcription, thereby regulating the G1-S transcriptional program. 136 This indicates that several substrates jointly control expression of G1-S signature genes, and that perturbation of the function of either substrate leads to transcriptional defects. Indeed, while mutation and inactivation of RB1 results in sustained expression of G1-S genes, including cyclin E, ablation of FOXM1 markedly reduces their expression in fibroblasts. 15 Feedback and feedforward signaling The G1-S transcriptional program is not restricted to genes that promote assembly of the pre-replication complex, origin firing, fork progression and maintenance, post-replication repair or other tasks associated with the mechanics and burden of DNA replication, but also comprises a panel of genes encoding signaling proteins that take part in positive and negative feedback or feedforward signaling. Prominent positive feedback signaling mediators are E2Fs, which induce transcription of their own genes, thereby maintaining the G1/S transcriptional program (Figure 3 ). In addition, E-cyclins and SKP2, the latter of which promotes proteasomal degradation of p27, activate CDK2. This kinase then contributes to substrate phosphorylation, thereby further increasing the transcription of G1-S genes 33, [137] [138] [139] (Figure 3 ). Perhaps the most important feedback signaling loop in the network is provided by RB1-mediated repression of CDKN2A/p16, a process that requires histone methylation by EZH2 and polycomb proteins at the CDKN2A locus. 140 It follows that sustained activation of cyclin D-dependent kinases results in increased expression of p16, which in turn restrains kinase activity (Figure 3) . In cancer cells, this negative feedback signaling loop is frequently uncoupled by loss of p16 or RB1 (loss of RB1 results in high-level expression of p16), principally associated with unscheduled transcription of G1/S signature genes. Among the latter are examples of feedforward signaling mediators, such as MYB, likely initiating subsequent transcriptional waves that allow cells to pass through the next stage of the cell cycle (Figure 3 ).
CYCLIN D-DEPENDENT KINASE FUNCTION IN CANCER BIOLOGY
Sustained CDK4/6 activation, presumably present in the majority of human tumors, endows cancer cells with the power to enter the cell cycle continuously. It does so by triggering the G1-S-phase transition switch while, at the same time, dramatically shortening the duration of the G1 phase (Figure 4) . 141, 142 It has became clear, however, that CDK4/6 also provide tumor cells with the powers to effectively counter senescence and apoptosis, two potent tumor suppressive mechanisms that must be overcome during cell immortalization and tumorigenesis (Figure 4 ). [14] [15] [16] [17] [18] [19] Consequently, acute inhibition of both kinases in combination in cancer cells, as well as tumors in vivo triggers cycle arrest, senescence and apoptosis, although the extent to which each of these three responses manifests seems to depend primarily on the cellular context. 14, 15 Cell cycle entry The activity of cyclin D-dependent kinases peaks in the late G1 phase, a narrow time window-coined the 'restriction point'-at which cells commit to cell cycle entry 143, 144 ( Figure 4 ). Once cells pass the restriction point, they no longer respond to mitogen withdrawal, but proceed with replication of their DNA (S-phase) and segregation of their duplicated chromosomes (M-phase). As mentioned in the second part of this review, cyclin D-dependent kinase-mediated phosphorylation of Retinoblastoma proteins, RB1, RBL1, and RBL2, activates E2F-mediated transcription of G1-S signature genes that ultimately cause cells to pass the restriction point and to enter S-phase 28, [95] [96] [97] [98] [99] [100] [101] (Figures 2b, 3 and 4) , but CDK4/ 6-FOXM1 signaling and phosphorylation of SMAD2 and SMAD3 also contribute to cell cycle entry 15, 102 (Figures 2c and d) . In most 'normal cells', G1-S-phase transitions are triggered by the synergistic action of cyclin D-and cyclin E-dependent kinases (CDK4/6 and CDK2, respectively). For example, combined genetic ablation of CDK4 and CDK6-or its activating subunits, cyclins D1, D2 and D3-in mice allows the development of the majority of tissues and organs, albeit the animals succumb to death at the late embryonic stage due to severe anemia. Mouse embryonic fibroblasts explanted from these mice proliferate nearly normally in vitro despite their reduced ability to exit quiescence and re-enter S-phase, whereas additional depletion of CDK2 from these knockout mouse embryonic fibroblasts virtually extinguishes cell proliferation. [145] [146] [147] In marked contrast to these observations, a wide variety of cancer cell lines are addicted to cyclin D-dependent kinase activity while CDK2 is largely dispensable for cell cycling, although exceptions from this do exist. 148, 149 This specific addiction reflects the central position the 'cyclin D-dependent kinase node' has in cancer cell-intrinsic mitogenic signaling networks, where CDK2 function has become non-redundant and thus unable to fully compensate for the loss of cyclin D-dependent kinase activity (Figure 3 ).
Senescence suppression Senescent cells are trapped in an irreversible state of cell cycle arrest, accompanied by other typical senescence hallmarks, including the senescence-associated secretory phenotype, the formation of heterochromatin foci, DNA-damage foci and the presence of b-galactosidase activity (b-Gal). 150 In cancer cells, cyclin D-dependent kinases counter senescence via phosphorylation of retinoblastoma proteins and FOXM1, thereby boosting the G1-S transcriptional program, comprising-among other genes-CCNE1 and CCNE2, E2Fs, MCMs, CDT1, RAD51, XRCC2 and MSH6 (Figure 4) . 15, 90 Although the exact mechanisms by which these signature genes suppress the cellular senescence program remains unclear, it is likely that they allow rapidly proliferating cancer cells to cope with oncogenic and spontaneous replication stress by, for example, promoting fork recovery, postreplicative repair and damage bypass, as well as licensing of dormant (that is, backup) replication origins. [151] [152] [153] [154] Conversely, genetic ablation of CDK4, or inhibition of its kinase activity by specific small-molecule inhibitors, triggers senescence in glioblastomas, breast and lung tumors in vivo. 13, 14, 16, 18 In a variety of breast cancer and human melanoma cell lines, but not in untransformed melanocytes, acute inhibition of CDK4/6 also manifests in profound senescence, which develops with varying robustness, usually within days after cell cycle arrest-with the highest response rates observed in melanoma cells or fully transformed melanocytes, independently of p53. 15, 90 The resulting abrupt cessation of expression of G1-S signature genes and the induction of reactive oxygen species may trigger persistent DNAdamage signaling, thereby implementing the senescence response in cancer cells, characterized by RB-mediated heterochromatin formation and irreversible silencing of E2F target genes. 91, [155] [156] [157] Apoptosis suppression Apoptosis is a highly regulated and ordered execution of cell death in response to extracellular or intracellular signals, accompanied by distinct cell morphological and molecular changes (Figure 4) . 158 In T-cell acute lymphoblastic leukemia (T-ALL) cells and derived in vivo xenotransplants, acute inhibition of CDK4/6 triggers apoptosis, but the apoptotic response in these cells is largely dependent on the presence of activating mutations in the NOTCH1 gene, found in more than 50% of human T-ALL cases where it fuels the expression of cyclin D3 (Figure 3 ). 14, [159] [160] [161] Consistent with this, acute genetic ablation of cyclin D3 in preformed NOTCH1-driven T-ALL in mice, or treatment with a specific CDK4/6 inhibitor, leads to the disappearance of leukemic cells by apoptosis and substantially prolonged survival without manifestation of adverse side effects. By contrast, treatment of NOTCH1 wild-type T-ALL cells, or cells derived from multiple myeloma, MCL or B-cell acute lymphoblastic leukemia, only results in cell cycle arrest and did not trigger apoptosis. 14 The execution of the apoptotic program in T-ALL cells seems to occur in a p53-independent fashion and is accompanied by induction of key pro-apoptotic genes, including Bcl2-interacting mediator of cell death (BIM) and components of the extrinsic apoptotic pathway, such as tumor necrosis factor and caspase 8, while pro-survival genes, like survivin, were transcriptionally repressed. By contrast, pro-apoptotic genes did not change in expression during manifestation of the senescence program in breast cancer cells. Thus, selective killing of T-ALL cells is effectuated by a specific apoptotic transcriptional program, which is normally suppressed by sustained CDK4/6 catalytic activity in this cell type. 14 Likewise, in Burkitt's lymphoma (BL) and germinal center B-cell-like diffuse large B-cell lymphoma (GBC-DLBCL), cyclin D-dependent kinases function to suppress cancer cell apoptosis, in addition to promoting cell cycle progression. 162 As observed with T-ALL cells, acute inhibition of CDK4/6 catalytic activity in a BL xenograft model led to virtual clearance of lymphoma cells from the animals. 162 It is important to note that both T-ALL and GBCderived malignancies (BL and GBC-DLBCL) are highly dependent on cyclin D3, 14, [163] [164] [165] whereas MCL, breast cancer and others that do not typically manifest cell-death responses upon CDK4/6 blockade tend to be much more reliant on cyclin D1 function. 166, 167 Whether the ability to suppress apoptosis in neoplastic cells is a function specifically exerted by cyclin D3 and its associated kinase subunit-assumed to be primarily CDK6 in T-ALL, BL and GBC-DLBCL cells-but not carried out by cyclin D1-CDK4 remains to be determined.
CYCLIN D-DEPENDENT KINASES AS DRUG TARGETS
A wealth of experimental data has identified CDK4 and CDK6 as prime targets for cancer therapy. First, at the genomic level, amplifications, mutations, chromosomal translocations and deletions of the kinases and their regulatory subunits are among the most common genetic alterations observed in human cancer; each of these genomic alterations is thought to result in sustained activation of CDK4 and CDK6 in tumor cells.
Second, both kinases constitute critical signaling mediators for several key oncoproteins, which act further upstream in the cellular signaling network and cause aberrant activation of CDK4/6 in a broad range of tumors. Third, preclinical studies-using both in vivo tumor models and numerous cancer cell lines-have shown that a variety of cancers are addicted to cyclin D-dependent kinase activity. Fourth, acute blockade of CDK4/6 triggers activation of intrinsic tumor suppression mechanisms that lead to irreversible growth arrest (senescence) or killing of tumor but not 'normal' cells. Lastly, cyclin D-dependent kinases are 'druggable' by ATP-competitive compounds, and slight conformational differences between the ATP-binding pockets of individual CDKs allow the design of highly selective, orally active CDK4/6 inhibitors.
Genomic alterations of the kinases and their regulatory subunits
The majority of human cancers maintain hyperactivation of cyclin D-dependent kinases through deletions, point mutations or promoter methylation of the CDKN2A tumor suppressor gene, encoding inhibitory p16, amplifications of cyclin D1, as well as amplifications or activating mutations of CDK4 or CDK6 itself. For a detailed discussion of each of the listed genomic alterations, the reader is directed to a recent review. 168 Here, we will highlight the nature and occurrence of the documented alterations of these loci on selected tumor types, for which unbiased genome-wide mutational and gene copy number analyses on hundreds of human specimens have recently become available. These data have largely confirmed earlier observations, albeit the incidence of the individual genetic mechanisms (amplifications, deletions, translocations, mutations or promoter methylation) and the identity of the targeted locus (CDKN2A, CCND1, CCND3 or CDK4) vary widely between tumor types.
CDKN2A, principally the most frequently deleted locus across human cancers, 7, 8 shows a homozygous deletion frequency of B50% or more in pancreatic cancers and glioblastomas-two of the least curable cancers-followed by B40% in melanomas. 9, 10, 169 In addition, B10% of pancreatic cancers and 19% of melanomas harbor inactivating mutations in CDKN2A, but transcriptional silencing by promoter methylation is also abundant. 170 In squamous cell lung cancers, CDKN2A is inactivated in 72% of cases, including promoter methylation (21%), inactivating mutation (18%), exon skipping (4%) and homozygous deletion (29%). 171 Amplifications of the cyclin D1 gene (CCND1) are common in breast cancer (B20%), melanoma (11%) and head and neck squamous cell carcinoma (B22%). 169, 172, 173 Moreover, the t(11;14)(q13;q32) chromosomal translocation-found in virtually all cases of MCL and 15-25% of multiple myelomas-places the cyclin D1 gene in immediate proximity to the strong immunoglobulin enhancers, thus dramatically increasing cyclin D1 expression in these malignancies. 174, 175 Single-nucleotide polymorphisms positioned within the cyclin D1 gene, such as G870A, impact on its alternative splicing in cancer cells and foster the expression of a truncated cyclin D1 protein, coined cyclin D1b, which lacks the critical C-terminal T286 residue; this curtails cyclin D1b's nuclear export and turnover, thus rendering the truncated isoform more oncogenic than the full-length protein. [176] [177] [178] Genomic alterations targeting the D-cyclin genes are, however, not limited to cyclin D1. For example, 38% of sporadic and 67% of HIV-associated cases of BL harbor recurrent point mutations in cyclin D3 that are thought to blunt its proteasomal turnover rate, thus causing stabilization of this cyclin protein.
162 CDK4 amplifications are also common in human cancers 7 and frequently observed in glioblastomas (B14%) and breast cancers, in particular the luminal B (25%) and HER2-expressing subtypes (24%). 10, 172 Point mutations of this kinase, primarily targeting residue R24, occur in melanomas and render the enzyme constitutively active by abrogating its ability to bind INK4 proteins. 2, 179, 180 Sustained kinase activation through oncogenic upstream signaling While B20% of human breast cancers harbor amplifications of the cyclin D1 gene, the protein is overexpressed in B50% of these tumors where it activates its kinase subunit. 181 This example highlights the fact that the mechanisms leading to aberrant regulation of cyclin D-dependent kinases are complex and not limited to alterations of the genomic loci listed above. As illustrated in Figure 3 and summarized in the first chapter of this review, the regulation of D-type cyclins and Cip/Kip subunits in particular is accomplished by a sheer number of converging upstream signaling pathways and proteins, many of which are targets of gene amplification, deletion and mutation themselves in neoplastic cells. We will highlight here representative examples of such 'distal' upstream signaling components that significantly contribute to hyperactivation of cyclin D-dependent kinases in cancers.
Human EGF receptor type 2 (HER2, or ERBB2) is a defining breast cancer oncogene amplified in B20% of cases. 172 Constitutively active HER2 and other receptor tyrosine kinases (RTKs), such as EGFR1, drive cyclin D1 expression via signaling through the canonical Ras-Raf-MAPK pathway, thereby enforcing excessive transcription of the cyclin D1 gene 35, 182 ( Figure 3 ). Accordingly, cyclin D1 is critically required for the formation of HER2 or Ras-induced breast cancers in mice. 166 RTK activation also slows the rate of cyclin D1 protein turnover by triggering PI3K-AktGSK3b signaling, which further contributes to cyclin D1 overexpression and kinase activation 41, 43, 46, 182, 183 (Figure 3) . In colorectal cancers, aberrant signaling through the Wnt-Apc-bcatenin axis-mostly due to loss of Apc or gain of b-catenin function-induces constitutive transcription of cyclins D1 and D2, mediated by the T-cell factor/lymphoid enhancer factor and its target gene, c-myc, respectively. 34, 148, 184 In the Apc Min/ þ mouse model of intestinal tumorigenesis, both D-cyclins act in a redundant kinase-dependent fashion to serve a critical role in initiation of colorectal cancer and proliferation of colorectal cancer cells. 185, 186 As indicated in the previous section, NOTCH1 is the defining oncogene of T-ALL, where it induces high-level expression of its target gene, cyclin D3, which in turn aberrantly activates its kinase subunit that drives this neoplasm. 14, 163, 187 Like D-type cyclins, Cip/Kip proteins are controlled by RTK signaling at several levels (Figure 3) , although the underlying mechanisms differ markedly. Akt directly phosphorylates p21 at T145 and p27 at T157, thereby curbing their nuclear import, thus reducing the ability of both proteins to form complexes with CDKs in the nucleus where critical substrates are localized. [188] [189] [190] [191] In addition, overexpression of the F-box protein SKP2-in large part also driven by mitogenic signaling cues, such as Akt-is frequently observed in tumors where it lowers the levels of Cips/Kips by mediating their proteasomal degradation. 138, 192 Thus, aberrant activation of RTK-PI3K-Akt signaling reduces the nuclear abundance of Cips/Kips while, at the same time, RTKs activate Src family kinases, which convert residual Cip/Kip proteins from an inhibitory to a CDK activation mode (Figure 1b, Figure 3 ). Although this scenario appears paradoxical at first glance, the overall implication is that overactive RTKs keep the nuclear abundance of Cips/Kips at only moderate levels while ensuring that each of these proteins is present in its CDK-activating state; this may allow activation of cyclin D-dependent kinases, as well as CDK2. Consistent with this, p27 haploinsufficient ( þ / À ) mammary epithelial cells are significantly more susceptible to HER2/ERBB2-driven proliferation and transformation than p27 þ / þ or p27
À / À cells. Likewise, cyclin D1 nuclear localization and CDK4 catalytic activity are reduced in p27 þ / þ and p27 À / À mammary epithelial cells. 193 Nevertheless, there will be cases where tumors express low levels of Cip/Kip proteins and where cyclin D-dependent kinases are inactive. As the abundance of p27 is also regulated by RB1 (RB1 promotes stabilization of the p27 protein), 194 this scenario may apply primarily to those cancers that are driven by RB1 deficiency and characterized by high-level expression of p16. 73, 79, 80 Specific small-molecule inhibitors Cyclin D-dependent kinases are susceptible to inhibition by ATP competitors that target the kinase's ATP-binding pocket, located between the N-and C-terminal lobes. This has, during the past (Figure 5a ), while docking of the pan-CDK inhibitor, aminopurvalanol, leaves much more room in the occupied pocket, with a smaller-binding interface between the compound and the kinase (Figure 5a ). Consequently, PD0332991 potently inhibits CDK4 and CDK6 in vitro (IC 50 's 0.011 and 0.016 mmol/l, respectively) with high selectivity over related kinases, such as CDK2 (IC 50 45 mmol/l), while pan-CDK inhibitors generally display little specificity for a given CDK. 93, 195, 196 Thus, for the first time, cyclin D-dependent kinase-addicted cancers can be effectively targeted in patients without the manifestation of major side effects, albeit treatment frequently involves neutropenia and thrombocytopenia.
197
PD0332991 and the recently developed high-specificity inhibitors LEE011 (Novartis/Astex) and LY2835219 (Elli-Lilly) are currently being tested in more than a dozen clinical trials against breast and a variety of advanced solid cancers, MCL, multiple myeloma and others (Table 2) . So far, significant tumor responses to PD0332991 were observed in patients with MCL, characterized by the t(11;14)(q13;q32) translocation (see above), and in RB1-positive advanced solid tumors. [197] [198] [199] Tumor responses to CDK4/6 inhibitors critically depend on the presence of functional RB1, principally associated with a low expression of p16 (CDKN2A), consistent with RB1's central role as a cyclin D-dependent kinase substrate and repressor of CDKN2A transcription (Figure 3) . 90, 92, 140, [200] [201] [202] Thus, evaluation of the p16 levels in human cancers may offer a tangible diagnostic approach to predict tumor responses to CDK4/6 inhibitors in patients. 203 Recent studies have further exposed the logic of using inhibitors of cyclin D-dependent kinases as 'magic bullets' against cancer. It is important to note that treatment of a variety of cancers with PD0332991 not only causes a transient halt of the cell cycle-which eventually allows these cells to resume cell cycle progression once drug treatment is discontinued-but triggers irreversible growth arrest (senescence) and selective killing of tumor cells (Figure 5b ). For example, in preclinical studies, robust senescence responses were observed in melanoma, glioblastoma, breast cancer, lung cancer and other tumor types while T-ALL and BL cells undergo profound apoptosis (Figure 5b ). [13] [14] [15] 18, 90, 162 CONCLUSIONS AND OUTLOOK Cyclin D-dependent kinases share features that make them stand out from their fellow CDK family members. Among those are their fastidious substrate specificity, their frequent involvement in genomic alterations in tumors, their susceptibility to INK4 inhibitors-specifically evolved to bind to CDK4 and CDK6-and their activation by Cip-Kip proteins. Although the advances made in our understanding on the regulation, function and pharmacological targeting of cyclin D-dependent kinases have been dramatic, major challenges lie ahead. As the complexity of the cellular signaling network controlled by cyclin D-dependent kinases unfolds, it becomes increasingly important to put individual signaling components and pathways into context and to understand the network dynamics in normal versus cancerous cells. It will also be crucial to unravel how CDK4/6 inhibitors activate intrinsic tumor suppressor mechanisms, that is, apoptosis or senescence, in cancer cells. Tilting the tumor cell's response to these specific inhibitors from a mere transient cell-cycle arrest towards the induction of the senescence and apoptotic programs may prove to be a robust way to achieve tumor remission in cancer patients. Perhaps this new generation of protein kinase inhibitors will provide the long-awaited 'magic bullets'-a term coined by the founder of chemotherapy, Paul Ehrlich, more than 100 years ago-for the fight against cancer. Abbreviations: CDK, cyclin-dependent kinase; ER, estrogen receptor; HER2, human EGF receptor type 2; RB, retinoblastoma protein.
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